JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

JNJ

227.58

-1.32%↓

ABT

91.21

-1.32%↓

MDT

83.38

-0.41%↓

A

115.41

+1%↑

VEEV

160.84

+3.11%↑

Search

Halozyme Therapeutics Inc

Fechado

SetorSaúde

65.35 -1.88

Visão Geral

Variação de preço das ações

24h

Atual

Mín

64.65

Máximo

65.55

Indicadores-chave

By Trading Economics

Rendimento

-317M

-142M

Vendas

98M

452M

P/E

Médio do Setor

27.176

60.328

Margem de lucro

-31.342

Funcionários

423

EBITDA

-3.5M

281M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+34.25% upside

Dividendos

By Dow Jones

Próximos Ganhos

5 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-1.1B

8.2B

Abertura anterior

67.23

Fecho anterior

65.35

Sentimento de Notícias

By Acuity

5%

95%

4 / 348 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Halozyme Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

24 de abr. de 2026, 19:19 UTC

Aquisições, Fusões, Aquisições de Empresas

Intertek Group Rejects EQT's Revised Offer

24 de abr. de 2026, 23:37 UTC

Aquisições, Fusões, Aquisições de Empresas

Scoring the Cook Era -- Barrons.com

24 de abr. de 2026, 20:51 UTC

Aquisições, Fusões, Aquisições de Empresas

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 de abr. de 2026, 20:50 UTC

Conversa de Mercado
Notícias Principais

Financial Services Roundup: Market Talk

24 de abr. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

24 de abr. de 2026, 20:39 UTC

Aquisições, Fusões, Aquisições de Empresas

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 de abr. de 2026, 20:09 UTC

Ganhos

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

24 de abr. de 2026, 19:48 UTC

Conversa de Mercado
Notícias Principais

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

24 de abr. de 2026, 19:25 UTC

Aquisições, Fusões, Aquisições de Empresas

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 de abr. de 2026, 19:25 UTC

Aquisições, Fusões, Aquisições de Empresas

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

24 de abr. de 2026, 19:22 UTC

Ganhos

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

24 de abr. de 2026, 19:06 UTC

Ganhos

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

24 de abr. de 2026, 19:05 UTC

Conversa de Mercado

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

24 de abr. de 2026, 18:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

24 de abr. de 2026, 18:28 UTC

Aquisições, Fusões, Aquisições de Empresas

Intertek Rejects Revised EQT Offer

24 de abr. de 2026, 18:12 UTC

Conversa de Mercado

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

24 de abr. de 2026, 18:06 UTC

Conversa de Mercado

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

24 de abr. de 2026, 17:42 UTC

Ganhos

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

24 de abr. de 2026, 17:28 UTC

Ganhos

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

24 de abr. de 2026, 17:28 UTC

Conversa de Mercado

Crypto Fear and Greed Index Slides Back to Neutral -- Market Talk

24 de abr. de 2026, 17:12 UTC

Conversa de Mercado

Global Equities Roundup: Market Talk

24 de abr. de 2026, 17:11 UTC

Conversa de Mercado

Apple Seen Gaining Market Share Despite Memory Crunch -- Market Talk

24 de abr. de 2026, 17:09 UTC

Conversa de Mercado
Ganhos

Intel Seen With Stronger Long-Term Earnings Power -- Market Talk

24 de abr. de 2026, 17:09 UTC

Aquisições, Fusões, Aquisições de Empresas

Organon Stock Surges on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

24 de abr. de 2026, 17:06 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Correction to Advanced Micro Devices Stock Gets Upgraded to Buy. Why It's the Big Winner of Intel Earnings. -- Barrons.com

24 de abr. de 2026, 16:51 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Two Big Loan Defaults Add to Pain in Private-Credit Funds -- WSJ

24 de abr. de 2026, 16:20 UTC

Conversa de Mercado
Ganhos

Tech, Media & Telecom Roundup: Market Talk

24 de abr. de 2026, 16:20 UTC

Conversa de Mercado
Notícias Principais

Financial Services Roundup: Market Talk

24 de abr. de 2026, 16:20 UTC

Conversa de Mercado
Ganhos

Auto & Transport Roundup: Market Talk

24 de abr. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

Comparação entre Pares

Variação de preço

Halozyme Therapeutics Inc Previsão

Preço-alvo

By TipRanks

34.25% parte superior

Previsão para 12 meses

Média 89.4 USD  34.25%

Máximo 96 USD

Mínimo 75 USD

Com base em 5 analistas de Wall Street que oferecem metas de preço de 12 meses para Halozyme Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

5 ratings

4

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

60.49 / 70.14Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

4 / 348 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Acima da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Halozyme Therapeutics Inc

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.
help-icon Live chat